SENTIEN BIOTECHNOLOGIES, INC.

Company Information

Company Name
SENTIEN BIOTECHNOLOGIES, INC.
Address
196 Boston Ave
MEDFORD, MA, 02155-4236
Phone
n/a
URL
n/a
DUNS
828970900
Number of Employees
4

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,314,291.00
4
SBIR Phase II
$3,759,234.00
2
Chart code to be here

Award List

  1. A Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failur

    Amount: $565,011.00

    DESCRIPTION (provided by applicant): The overall goal of this Phase I project is to create technical protocols for the reproducible operation of our proprietary cell-based device for the treatment of ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. SBIR Phase I:Assembly and Storage of Cell-Derived Drug Delivery Devices

    Amount: $150,000.00

    This Small Business Innovation Research (SBIR) Phase I project proposes the development of a stem cell-based extracorporeal device that can offer unparalleled support to 200,000+ patients undergoing s ...

    SBIR Phase I 2010 National Science Foundation
  3. Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal Failure

    Amount: $773,285.00

    DESCRIPTION (provided by applicant): The overall goal of this project is to design a clinical protocol for the operation and monitoring of a mesenchymal stem cell (MSC)-coated dialysis device for the ...

    SBIR Phase II 2012 Department of Health and Human Services
  4. Blood Purification for Organ Failure

    Amount: $99,974.00

    Sentien Biotechnologies is developing cellular devices for the treatment of acute organ failure, including polytrauma-induced multiple organ dysfunction syndrome (MODS). Our flagship product, the Sent ...

    SBIR Phase I 2012 Department of Defense
  5. Cellular Device for the Treatment of Acute Liver Failure

    Amount: $499,306.00

    DESCRIPTION (provided by applicant): The goal of this Phase I project is to develop a cell-coated device for the treatment of acute liver failure. The device harnesses mesenchymal stem cell secretions ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive

    Amount: $2,985,949.00

    DESCRIPTION (provided by applicant): The goal of this Phase IIB SBIR application is to test the Sentien cellular bioreactor product (the Sentinel ) in a first-in-man study to assess safety and prelimi ...

    SBIR Phase II 2014 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government